BRISTOL MYERS SQUIBB

EpiVax, a leader in preclinical immunogenicity assessment for biologic therapeutics and vaccines, has appointed Dr. Vibha Jawa as Chief Scientific Officer, succeeding founder Dr. Annie De Groot who transitions to Chief Medical Officer.

TQ Therapeutics has acquired Juno Therapeutics GmbH from Bristol Myers Squibb through a share purchase agreement with undisclosed financial terms.

Acadia Pharmaceuticals has appointed Allyson McMillan-Youngblood as Senior Vice President, Rare Disease Franchise, bringing over 20 years of pharmaceutical industry experience.

Syndeio Biosciences launched with $90 million in funding to develop the first synapse-targeted therapeutics for neurological and psychiatric disorders affecting over one billion people globally.

GlycoEra raised $130 million in Series B funding led by Novo Holdings to advance its lead protein degrader GE8820 into first-in-human clinical trials.

The 15th World ADC San Diego conference (November 4-7, 2024) represents the industry's largest and most comprehensive ADC-focused forum, featuring 120+ speakers across six development tracks.

Prothena's Phase 3 AFFIRM-AL trial of birtamimab for AL amyloidosis failed to meet its primary endpoint of time to all-cause mortality (HR=0.915, p-value=0.7680).

Zanzalintinib combined with nivolumab demonstrated a 63% objective response rate and 90% disease control rate in previously untreated advanced clear cell renal cell carcinoma patients.

The Dementia Discovery Fund (DDF), managed by SV Health Investors, has closed its second fund with $269 million in commitments, bringing its total raised capital to over $550 million for dementia therapeutics development.

Tubulis announced that the first antibody-drug conjugate from its strategic partnership with Bristol Myers Squibb has entered clinical development, marking a significant milestone in their 2023 collaboration agreement.